中国医疗-2025 年国家医保目录与首批创新药医保谈判公布：我们覆盖的标的医保目录结果良好，有望推动增长

The National Healthcare Security Administration (NMPA) on 7 Dec held a conference to update on the 2025 version of national reimbursement drug list (NRDL), along with the launch of the commercial health insurance innovative drug directory (CHIIDD). In detail, 114 new drugs (including 50 type 1 innovate drugs) were added while 29 drugs were removed from the NRDL, making the total number of drugs in the list to 3,253. The success rate of new drug negotiation is 88%, higher than 76% in 2024. The highly- antici ...